npj Breast Cancer (Dec 2021)

Population-based estimates of breast cancer risk for carriers of pathogenic variants identified by gene-panel testing

  • Melissa C. Southey,
  • James G. Dowty,
  • Moeen Riaz,
  • Jason A. Steen,
  • Anne-Laure Renault,
  • Katherine Tucker,
  • Judy Kirk,
  • Paul James,
  • Ingrid Winship,
  • Nicholas Pachter,
  • Nicola Poplawski,
  • Scott Grist,
  • Daniel J. Park,
  • Bernard J. Pope,
  • Khalid Mahmood,
  • Fleur Hammet,
  • Maryam Mahmoodi,
  • Helen Tsimiklis,
  • Derrick Theys,
  • Amanda Rewse,
  • Amanda Willis,
  • April Morrow,
  • Catherine Speechly,
  • Rebecca Harris,
  • Robert Sebra,
  • Eric Schadt,
  • Paul Lacaze,
  • John J. McNeil,
  • Graham G. Giles,
  • Roger L. Milne,
  • John L. Hopper,
  • Tú Nguyen-Dumont

DOI
https://doi.org/10.1038/s41523-021-00360-3
Journal volume & issue
Vol. 7, no. 1
pp. 1 – 7

Abstract

Read online

Abstract Population-based estimates of breast cancer risk for carriers of pathogenic variants identified by gene-panel testing are urgently required. Most prior research has been based on women selected for high-risk features and more data is needed to make inference about breast cancer risk for women unselected for family history, an important consideration of population screening. We tested 1464 women diagnosed with breast cancer and 862 age-matched controls participating in the Australian Breast Cancer Family Study (ABCFS), and 6549 healthy, older Australian women enroled in the ASPirin in Reducing Events in the Elderly (ASPREE) study for rare germline variants using a 24-gene-panel. Odds ratios (ORs) were estimated using unconditional logistic regression adjusted for age and other potential confounders. We identified pathogenic variants in 11.1% of the ABCFS cases, 3.7% of the ABCFS controls and 2.2% of the ASPREE (control) participants. The estimated breast cancer OR [95% confidence interval] was 5.3 [2.1–16.2] for BRCA1, 4.0 [1.9–9.1] for BRCA2, 3.4 [1.4–8.4] for ATM and 4.3 [1.0–17.0] for PALB2. Our findings provide a population-based perspective to gene-panel testing for breast cancer predisposition and opportunities to improve predictors for identifying women who carry pathogenic variants in breast cancer predisposition genes.